Spots Global Cancer Trial Database for Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)
Official Title: Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)
Study ID: NCT00640523
Conditions
Interventions
Study Description
Brief Summary: To evaluate the effectiveness and safety of forodesine in CLL patients
Detailed Description: To investigate the efficacy (complete response \[CR\] + partial response \[PR\]) of forodesine in treating subjects with CLL who have failed at least one prior treatment regimen or who are treatment naïve but are either elderly, have poor performance status or are otherwise predicted not to tolerate cytotoxic chemotherapy.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Tower Cancer Research Foundation, Beverly Hills, California, United States
UCLA Medical Center, Los Angeles, California, United States
Indiana University Cancer Pavillion, Indianapolis, Indiana, United States
Center for Cancer & Blood Disorders, PC, Bethesda, Maryland, United States
Washington University School of Medicine, St. Louis, Missouri, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Weill Cornell Medical College, New York, New York, United States
Oregon Health & Science University, Portland, Oregon, United States
Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
Frankston Hospital, Frankston, Victoria, Australia
Cabrini Hospital, Malvern, Victoria, Australia
Contact Details
Name: Asher Chanan-Khan, MD
Affiliation: Roswell Park Cancer Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
